ENZYMES
& ASSAY KITS

NOVOCIB's IMPDH II is a human recombinant Inosine Monophosphate Dehydrogenase Type II expressed in E. coli. It has an apparent molecular weight of ca. 56 kDa.
Inosine monophosphate dehydrogenase converts inosine 5’-monophosphate to xanthine 5’-monophosphate using NAD⁺ as a cofactor. IMPDH is involved in de novo guanine nucleotide biosynthesis. It plays a major role in cell growth and in the malignancy of some tumors. Additionally, guanine nucleotide is needed for lymphocyte proliferation.
IMPDH II is the predominant isoform of IMPDH. It is recognized as a validated target to treat a wide range of cancers and infectious diseases and to prevent lymphocytes proliferation (see above).

Storage: –70 °C in a solution containing 50 mM KH2PO4, pH 8.0, 1 mM EDTA, 0.1 mM DTT, 50% glycerol. Unit Definition: One unit of IMPDH Type II catalyzes the oxydation of 1 µmole of IMP to XMP per minute at pH 7.8 at 37 °C Specific Activity: ≥ 0.150 unit/mg protein. Purity controlled by SDS-PAGE IMPDH activity was confirmed by HPLC analysis for quantification of IMP, XMP, NAD and NADH

Assay condition: KH2PO4 0.1M, pH7.8, NAD 180µM, DTT 1mM, 0.13mU of human recombinant IMPDH II (2µl at 0.081 U/mg protein) Incubation at 25°C. Reaction started by adding IMP at various concentrations. NADH formation was measured in an iEMS Reader MF (Labsystems, Finland) microtiter plate reader at 340nm. At 25°C, VMax = 0.8 µM.mn-1, KM = 124.4 µM

Catalytic activity
Inosine Monophosphate Dehydrogenase (IMPDH) converts inosine 5’-monophosphate (IMP) to xanthosine 5’- monophosphate (XMP) using NAD⁺ as a cofactor. The oxidation of IMP to XMP is considered as the pivotal step in the biosynthesis of guanine nucleotide, whose pool controls cell proliferation and many other major cellular processes⁽¹⁾. The decrease in guanine nucleotide resulting from IMPDH inhibition interrupts the nucleic acid synthesis in proliferating cells. The involvement of IMPDH in de novo guanine nucleotide biosynthesis makes IMPDH a crucial enzyme in cell proliferation and differentiation⁽²⁾. IMPDH is recognized as a validated target for several major therapeutic areas. IMPDH inhibitors are exploited as antiviral (e.g. ribavirine), antiparasitic, antimicrobial, antileukemic and immunosuppressive agents⁽²⁾. IMPDH Type II is the predominant isoform of the enzyme and is selectively expressed in proliferating cells, including lymphocytes and tumor cells⁽²⁾.
IMPDH in immunology
IMPDH is highly active in lymphocytes. It is a validated target to treat immunological diseases and to induce immunosuppression (CellCept^®, a mycophenolic acid (MPA) prodrug - Roche – CHF1.85 Bn as an immunosuppressive agent in 2006, orphan drug designation in 2006 for Myasthenia Gravis; CellCept^® reached positive results in Phase III trials in Lupus Nephritis). IMPDH is also recognized as an excellent target for the treatment of psoriasis, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)⁽³⁾.
IMPDH in oncology
IMPDH, and particularly Type II, which is overexpressed in tumor cells, is considered as a highly potent target for cancer chemotherapy^{(1, 2, 4, 5)}. Several IMPDH inhibitors are under development for the treatment of Acute and Chronic Myelogenous Leukemia (AML, CML)⁽⁶⁾ and other cancers (pancreas, colon, bladder…). Additionally, it has been shown that the use of IMPDH inhibitors counteracts the drug resistance⁽⁷⁾ that may appear in certain tumors. For instance, methotrexate resistance is directly related to the overexpression of IMPDH, whose inhibition restores the drug efficacy⁽⁸⁾. Combination with other anti-cancer drugs extends the potential application of IMPDH inhibitors.
Current development of IMPDH inhibitors
CellCept^®, ribavirin, mizoribine and tiazofurine are examples of currently used drugs that target IMPDH. Benzamide riboside, tiazofurine, MPA are under development in Phase II/III in leukemia: results are judged very encouraging⁽⁸⁾.
The IMPDH II atomic structure has been resolved and it provides a valuable background for further leads optimization⁽⁹⁾. Besides nucleosides analogues, NCEs have been identified as IMPDH inhibitors^{(10, 11, 12, 13, 14)} and enter development trials (e.g. AVN-944: Phase I in advanced hematologic malignancies, Phase II in pancreatic and other solid tumors).
All this demonstrates how promising new IMPDH inhibitors could be and why the inhibiting activity of compounds is worth being evaluated on such a highly pertinent target.

AVN-944	VX-148	VX-497
MPA (mycophenolic acid)	CellCept®	BMS-337197
Tiazofurin	Ribavirine	Mizoribine

(^Top)

References (with links to PubMed) 1. L. Hedstrom and L. Gan (2006): IMP dehydrogenase: structural schizophrenia and an unusual base Curr. Opin. Chem. Biol. 10(5), 520-525 2. B. J. Barnes et al. (2001): Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: Potent inhibitors of human type II inosine 5'-monophosphate dehydrogenase Int. J. Cancer. 94(2), 275–281 3. R. E. Beevers et al. (2006): Low molecular weight indole fragments as IMPDH inhibitors Bioorg. Med. Chem. Lett. 16(9), 2535-2538 4. L. Chen and K. W. Pankiewicz (2007): Recent development of IMP dehydrogenase inhibitors for the treatment of cancer Curr. Opin. Drug Discov. Devel. 10(4):403-12 ( Review) 5. B. J. Barnes et al. (2001): Induction of Tmolt4 Leukemia Cell Death by 3,3-Disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: Specificity for Type II Inosine 5'-Monophosphate Dehydrogenase J. Pharm. Exp. Therap. 298(2), 790-796 6. K. Malek et al. (2004): Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia Leukemia Research 28, 1125–1136 7. L. Hong et al. (2006): ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2 Biochem. Cell Biol. 84(2): 199–206 8. S. Peñuelas et al. (2005): Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells FEBS 272, 696–710 9. T. D. Colby et al. (1999): Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design PNAS, 96(7), 3531–3536 10. E. J. Iwanowicz et al. (2003): Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety Bioorg. Med. Chem. Lett. 13(12), 2059-2063 11. J. Jain et al. (2002): Characterization of pharmacological efficacy of VX-148, a new potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor J. Pharm. Exp. Therap. 302(3), 1272-1277 12. J. Jain et al. (2004): Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes Biochem. Pharmacol. 67(4), 767-776 13. G. M. Buckley et al. (2005): Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure–activity relationships Bioorg. Med. Chem. Lett. 15(3), 751-754 14. T. G. Murali Dhar et al. (2003): 3-Cyanoindole-Based Inhibitors of Inosine Monophosphate Dehydrogenase: Synthesis and Initial Structure–Activity Relationships Bioorg. Med. Chem. Lett. 13(20), 3557-3560